TORONTO, ON — November 19, 2025 — Leads & Copy — Biomind Labs Inc. (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) has filed continuous disclosure documents on SEDAR+ and announced the appointment of Scott Ackerman as an independent director.
The company filed amended and restated management’s discussion and analysis (MD&A) and officers’ certificates for the year ended December 31, 2024, and for the three-month periods ended March 31, 2025, and June 30, 2025. Additionally, it filed interim unaudited financial statements, management’s discussion and analysis, and officers’ certificates for the nine months ended September 30, 2025.
The filings address a corrective disclosure request from the Ontario Securities Commission (the “Commission”) following a staff review. The amendments include clarifications to the company’s business operations and drug candidate programs, detailed explanations of operational results compared to previous periods, and the addition of audit committee and corporate governance disclosure for the year ended December 31, 2024.
Biomind Labs also announced the appointment of Scott Ackerman as an independent director to its Board of Directors and Audit Committee. Ackerman is the CEO of Emprise Capital Corp. and serves as a director and audit committee chair for several Canadian listed public companies.
The Company is subject to a cease trade order (FFCTO) issued on April 4, 2025, by the Commission due to the failure to file audited financial statements for the year ended December 31, 2024, and related documents. Consequently, the interim financial statements for the three-month period ending March 31, 2025, Form 51-102F6 – Statement of Executive Compensation, the interim financial statements for the six-month period ending June 30, 2025, and the interim financial statements for the nine-month period ending September 30, 2025, were not filed by their due dates of May 15, 2025, May 20, 2025, August 14, 2025, and November 14, 2025, respectively.
The Company has filed the annual financial statements, amended & restated management’s discussion and analysis and officers certificates for the fiscal year ended December 31, 2024, the interim unaudited financial statements, amended & restated management’s discussion and analysis and officers certificates for the three-month period ending March 31, 2025 and the six-month period ending June 30, 2025, the annual information form for the year ended December 31, 2024, Form 51-102F6 – Statement of Executive Compensation, and the interim unaudited financial statements, management’s discussion & analysis and officers certificates for the nine-month period ending September 30, 2025, which are available on SEDAR+ at www.sedarplus.ca.
Alejandro Antalich, Chief Executive Officer, can be reached by email at future@biomindlabs.com or by telephone at + 598 97 663166.
Biomind Labs is a biotech research and development company focused on transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of key endogenous substances which are occurring in the human body and an organic compound that includes many neurotransmitters for treating a wide range of therapeutic indications. Biomind Labs is dedicated to providing patients with access to affordable and contemporary treatments.
